Tetravil (F8-IL4) is an immunocytokine, composed of the F8 antibody that recognizes the alternatively spliced EDA domain of fibronectin coupled with the immunoregulatory cytokine interleukin 4 (IL-4). The localization and retention of IL-4 allows an increased therapeutic index of the cytokine specifically at the sites of disease.
Tetravil shows unprecedented therapeutic activity in a mouse model of Rheumatoid Arthritis. Experimental studies showed that arthritic mice could be cured from established disease by the administration of Tetravil in combination with dexamethasone.
Tetravil is the first immunocytokine in Philogen's pipeline that is showing activity in both oncology and autoimmune disease indications. The product has shown potent activity also in immunocompetent model of psoriasis, experimental autoimmune encephalomyelitis and endometriosis.
Kawalkowska et al. (2016) Eur. J. Immunol. 46:1246-57;
Quattrone et al. (2015) Reprod. Science 22:1143-1152;
Hemmerle et al. (2015) J. Dermatology 76:96-103;
Hemmerle and Neri (2014) Int. J. Cancer 134:467-77;
Hemmerle et al. (2014) EULAR, Paris;
Hemmerle et al. (2014) Proc. Natl. Acad. Sci. USA 111:12008-12.